DTC Prescription Drug Advertising: The History and Impact of FDA Regulation

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Hartgraves, Tiffany	en_US
dc.date.accessioned	2012-06-07T20:11:39Z
dc.date.issued	2002	en_US
dc.identifier.citation	DTC Prescription Drug Advertising: The History and Impact of FDA Regulation (2002 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852117
dc.description.abstract	This paper traces the history of direct-to-consumer (DTC) advertising for prescription drugs in the United States, beginning with the enactment of the Federal Food, Drug, and Cosmetics Act in 1938 and continuing through the current state of FDA regulation. A detailed analysis of how the promulgation of DTC ads has affected a variety of groups (including consumers, the medical profession, pharmaceutical companies, the government, and advertisers) is followed by a brief look at a well-known DTC ad campaign (Schering-Ploughâ€™s Claritin). The paper questions whether DTC ads are a constructive or a deconstructive element of the American healthcare system and concludes by offering an opinion on the current state of DTC advertising regulation and enforcement by the FDA.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	DTC	en
dc.subject	advertising	en
dc.subject	policy	en
dc.subject	drugs	en
dc.title	DTC Prescription Drug Advertising: The History and Impact of FDA Regulation	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T20:11:39Z